FIELD: biochemistry; pharmaceuticals; medicine.
SUBSTANCE: group of inventions relates to the use of enisamium iodide to reduce inflammatory reactions in humans during acute respiratory infections. The following is disclosed: the use of a composition containing the active substance enisamium iodide in an effective amount to inhibit the expression of genes encoding “ЦОГ-1”, 2, NF-κB, IL-1, IL-6, TGF1b, increase the expression of mRNA in the blood, the production of IL-10 and secretion of the anti-inflammatory cytokine IL-10 by mononuclear cells.
EFFECT: expansion of the range of agents for a specific purpose.
6 cl, 17 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INHIBITING NUCLEAR KAPPA B FACTOR WITH USING 2-ETHYL-6-METHYL-3-HYDROXIPIRIDINIUM L-2,6-DIAMINOHEXANOATE IN CULTURE OF CELLS | 2017 |
|
RU2669348C1 |
| METHOD FOR INHIBITING NUCLEAR FACTOR KAPPA B WITH USE OF 5-HYDROXYNICOTINATE 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE IN CELL CULTURE | 2017 |
|
RU2674443C1 |
| DRUG WITH ANTI-INFLAMMATORY ACTIVITY | 2016 |
|
RU2617123C1 |
| MODULATION OF EXPRESSION OF STAT-1-DEPENDED GENES | 2002 |
|
RU2311456C2 |
| USE OF ARSENIC COMPOUNDS TO TREAT TISSUE OR ORGAN REJECTION | 2013 |
|
RU2665362C2 |
| USE OF ARSENIC COMPOUNDS FOR PAIN MANAGEMENT AND INFLAMMATION TREATMENT | 2008 |
|
RU2630574C2 |
| KALEBIN A FOR TREATMENT OF OSTEOPOROSIS | 2016 |
|
RU2653103C2 |
| METHOD OF INHIBITING KAPPA NUCLEAR FACTOR WITH THE USE OF POTASSIUM 5-HYDROXYNICOTINATE IN A CELL CULTURE | 2017 |
|
RU2675693C1 |
| INHIBITING OF STAT-1 | 2002 |
|
RU2311910C2 |
| COMPOSITION FOR STIMULATING DENDRITIC CELL MATURATION, CONTAINING HYBRID PROTEIN RV2299C/ESAT-6 | 2017 |
|
RU2733886C2 |
